DNA - NYSE

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc.

DNA·NYSE

$8.73

-6.4%
HealthcareBiotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$570.28M
EPS-5.6400
P/E Ratio-1.55
Earnings Date08/06/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. Earnings Call Transcripts

DNA · NYSE

Related Guides

Blog Categories

Continue your DNA research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.